CAMBRIDGE, Mass., Dec. 20, 2011 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced today the appointment of Sandford D. Smith to its Board of Directors, effective January 1, 2012. Mr. Smith will also serve as a member of the Audit Committee. The Board also announced today the resignation of Alison Kiley as a Director, effective January 1, 2012.
